

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) are hyperlinks to full guidance	Titles	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
				Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2011-12					
Atrial fibrillation - dabigatran etexilate (TA249)		31/03/2012	Dabigatran – a recommended option for atrial fibrillation patients with risk factors to prevent stroke and embolism.	Yes	
Rheumatoid arthritis - tocilizumab (TA247) Update to TA198		29/02/2012	Tocilizumab (with methotrexate) – a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated.	Yes	
Diabetes (type 2) - exenatide (prolonged release) (TA248)		29/02/2012	Exenatide prolonged release – a recommended option in combination with oral drugs for selected patients with type 2 diabetes	Yes	
Venom anaphylaxis - immunotherapy pharmlagen (TA246)		29/02/2012	Pharmlagen – a recommended treatment for bee or wasp venom allergy after a severe reaction, or moderate reaction in certain circumstances.	No	This medicine is not applicable to C&W
Venous thromboembolism (hip and knee surgery) - apixaban (TA245)		31/01/2012	Apixaban – a recommended option to reduce thromboembolism after knee/hip replacement.	Yes	
Chronic obstructive pulmonary disease - roflumilast (TA244)		31/01/2012	Roflumilast – only recommended as part of a clinical trial.	Yes	
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (TA242) Review of TA150 and part review of TA118		31/01/2012	Cetuximab – not recommended alone or in combination. Bevacizumab – not recommended with fluoropyrimidines. Panitumumab – not recommended.	Yes	
Follicular lymphoma - rituximab (TA243) Update to TA110		31/01/2012	Rituximab – recommended in combination for first line treatment of stage III–IV disease.	Yes	
Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) (TA241)		31/01/2012	Dasatinib – not recommended. Nilotinib – recommended for Philadelphia-chromosome-positive CML if standard dose imatinib unsuccessful or unsuitable. Imatinib high dose – not recommended if disease has progressed after standard dose.	Yes	
Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)		31/12/2011	Tocilizumab – recommended if NSAIDs, steroids and methotrexate have failed.	Yes	
Breast cancer (metastatic) - fulvestrant (TA239)		31/12/2011	Fulvestrant – not recommended post-menopause in oestrogen dependent metastatic disease, or if disease returned/worsened after anti-oestrogens.	No	This medicine is not applicable to C&W
Colorectal cancer (metastatic) - panitumumab (terminated appraisal) (TA240)		31/12/2011	Panitumumab – unable to recommend NHS use. TA terminated due to lack of evidence submission.	No	NICE are unable to recommend this medicine for this indication

Macular oedema (diabetic) - ranibizumab (TA237)	30/11/2011	Ranibizumab – not recommend for people with diabetic macular oedema.	Yes	
Osteosarcoma - mifamurtide (TA235)	31/10/2011	Mifamurtide – recommended as a treatment for specified children, adolescents and young adults with osteosarcoma.	No	This medicine is not applicable to C&W
Acute coronary syndromes - ticagrelor (TA236)	31/10/2011	Ticagrelor – recommended combined with low-dose aspirin for up to a year as a treatment for specified people with acute coronary syndromes.	Yes	
Ankylosing spondylitis - golimumab (TA233)	31/08/2011	Golimumab – a recommended option for severe, active ankylosing spondylitis in the same circumstances as TA143 when NSAIDs unsuccessful.	Yes	
Rheumatoid arthritis - abatacept (2nd line) (TA234)	31/08/2011	Abatacept – not recommended with methotrexate in moderate to severe RA if DMARDs ineffective.	Yes	
Macular oedema (retinal vein occlusion) - dexamethasone (TA229)	31/07/2011	Dexamethasone intravitreal implant – recommended for specified people with macular oedema due to retinal vein occlusion.	Yes	
Depression - agomelatine (terminated appraisal) (TA231)	31/07/2011	Agomelatine – unable to recommend NHS use for major depressive episodes. TA terminated due to lack of evidence submission.	No	NICE are unable to recommend this medicine for this indication
Epilepsy (partial) - retigabine (adjuvant) (TA232)	31/07/2011	Retigabine – a recommended adjunctive option for partial onset seizures with or without secondary generalisation in some people with epilepsy.	Yes	
Multiple myeloma (first line) - bortezomib and thalidomide (TA228)	31/07/2011	Thalidomide – a recommended option for specified people with multiple myeloma. Bortezomib – a recommended option only if thalidomide not tolerated or suitable.	Yes	
Myocardial infarction (persistent ST-segment elevation) - bivalirudin (TA230)	31/07/2011	Bivalirudin – recommended as a possible treatment for adults with STEMI having percutaneous coronary intervention.	No	This medicine is not applicable to C&W
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) (TA227)	30/06/2011	Erlotinib – not recommended as maintenance after platinum-chemotherapy.	Yes	
Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)	30/06/2011	Rituximab – recommended as a possible treatment to maintain remission.	Yes	
Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab (TA225)	30/06/2011	Golimumab – a recommended option (in the same circumstances as TA130) after other specified treatments have failed or not been tolerated.	Yes	
Rheumatoid arthritis (methotrexate-naïve) - golimumab (terminated appraisal) (TA224)	30/06/2011	Golimumab – unable to recommend NHS use. TA terminated due to lack of evidence submission.	No	NICE are unable to recommend this medicine for this indication
Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate (TA223)	31/05/2011	Naftidrofuryl oxalate – a recommended option for intermittent claudication in peripheral arterial disease. Cilostazol, pentoxifylline and inositol nicotinate – not recommended.	Yes	

Thrombocytopenic purpura - romiplostim (TA221)	30/04/2011	Romiplostim – recommended for specified people with chronic, severe, and refractory ITP.	Yes	
Ovarian cancer (relapsed) - trabectedin (TA222)	30/04/2011	Trabectedin – not recommended with pegylated liposomal doxorubicin for relapsed platinum-sensitive ovarian cancer.	Yes	
Psoriatic arthritis - golimumab (TA220)	30/04/2011	Golimumab – recommended as a possible treatment after trying other DMARDs in the same circumstances as TA199.	Yes	
Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)	30/04/2011	Everolimus – not recommended	Yes	